Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01135186 · ClinicalTrials.gov registry record · NA
Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT01135186: Completed NA study, sponsored by Stanford University.
NCT01135186 is a NA study that has completed, run by Stanford University. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01135186, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
Kuvan® (sapropterin dihydrochloride) for Improving Gastric Accommodation in Women with Diabetic Gastroparesis (KIGA-DG)
Interventions
- DRUG sapropterin dihydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01135186
The ClinicalTrials.gov registry entry for NCT01135186 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sapropterin dihydrochloride is the first listed.
NCT01135186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01135186 about?
NCT01135186 is a clinical study titled "Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.". Kuvan® (sapropterin dihydrochloride) for Improving Gastric Accommodation in Women with Diabetic Gastroparesis (KIGA-DG)
What is the current status of trial NCT01135186?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2010-05. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01135186?
The interventions under investigation include: sapropterin dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT01135186?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.